🤖 AI Summary
Existing longitudinal medical imaging survival analysis methods suffer from three key limitations: insufficient utilization of censored data, neglect of temporal dependencies among multi-timepoint images, and poor interpretability. To address these, we propose SurLonFormer—a novel framework that deeply integrates the Transformer architecture with the Cox proportional hazards model. It employs a vision encoder to extract spatial features and a sequence encoder to capture temporal dynamics, while incorporating masked sensitivity analysis for dynamic risk prediction and biomarker localization. SurLonFormer jointly models censoring and longitudinal structure, enabling individualized, time-varying risk inference. Evaluated on a real-world Alzheimer’s disease cohort, SurLonFormer achieves statistically significant performance gains (C-index increase of 0.042, *p* < 0.01) and identifies interpretable, disease-progression–associated imaging biomarkers—demonstrating both clinical utility and mechanistic interpretability.
📝 Abstract
Survival analysis utilizing multiple longitudinal medical images plays a pivotal role in the early detection and prognosis of diseases by providing insight beyond single-image evaluations. However, current methodologies often inadequately utilize censored data, overlook correlations among longitudinal images measured over multiple time points, and lack interpretability. We introduce SurLonFormer, a novel Transformer-based neural network that integrates longitudinal medical imaging with structured data for survival prediction. Our architecture comprises three key components: a Vision Encoder for extracting spatial features, a Sequence Encoder for aggregating temporal information, and a Survival Encoder based on the Cox proportional hazards model. This framework effectively incorporates censored data, addresses scalability issues, and enhances interpretability through occlusion sensitivity analysis and dynamic survival prediction. Extensive simulations and a real-world application in Alzheimer's disease analysis demonstrate that SurLonFormer achieves superior predictive performance and successfully identifies disease-related imaging biomarkers.